Clinical trials needed to evaluate compression therapy in breast cancer related lymphedema (BCRL). Proposals from an expert group
Identifieur interne : 000213 ( PascalFrancis/Corpus ); précédent : 000212; suivant : 000214Clinical trials needed to evaluate compression therapy in breast cancer related lymphedema (BCRL). Proposals from an expert group
Auteurs : H. Partsch ; N. Stout ; I. Forner-Cordero ; M. Flour ; C. Moffatt ; A. Szuba ; D. Milic ; G. Szolnoky ; H. Brorson ; M. Abel ; J. Schuren ; F. Schingale ; S. Vignes ; N. Piller ; W. DöllerSource :
- International angiology [ 0392-9590 ] ; 2010.
Descripteurs français
- Pascal (Inist)
English descriptors
Abstract
Aim. A mainstay of lymphedema management involves the use of compression therapy. Compression therapy application is variable at different levels of disease severity. Evidence is scant to direct clinicians in best practice regarding compression therapy use. Further, compression clinical trials are fragmented and poorly extrapolable to the greater population. An ideal construct for conducting clinical trials in regards to compression therapy will promote parallel global initiatives based on a standard research agenda. The purpose of this article is to review current evidence in practice regarding compression therapy for BCRL management and based on this evidence, offer an expert consensus recommendation for a research agenda and prescriptive trials. Recommendations herein focus solely on compression interventions. Methods. This document represents the proceedings of a session organized by the International Compression Club (ICC) in June 2009 in Ponzano (Veneto, Italy). The purpose of the meeting was to enable a group of experts to discuss the existing evidence for compression treatment in breast cancer related lymphedema (BCRL) concentrating on areas where randomized controlled trials (RCTs) are lacking. Results. The current body of research suggests efficacy of compression interventions in the treatment and management of lymphedema. However, studies to date have failed to adequately address various forms of compression therapy and their optimal application in BCRL. We offer recommendations for standardized compression research trials for prophylaxis of arm lymphedema and for the management of chronic BCRL. Suggestions are also made regarding; inclusion and exclusion criteria, measurement methodology and additional variables of interest for researchers to capture. Conclusion. This document should inform future research trials in compression therapy and serve as a guide to clinical researchers, industry researchers and lymphologists regarding the strengths, weaknesses and shortcomings of the current literature. By providing this construct for research trials, the authors aim to support evidence-based therapy interventions, promote a cohesive, standardized and informative body of literature to enhance clinical outcomes, improve the quality of future research trials, inform industry innovation and guide policy related to BCRL.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 11-0052630 INIST |
|---|---|
| ET : | Clinical trials needed to evaluate compression therapy in breast cancer related lymphedema (BCRL). Proposals from an expert group |
| AU : | PARTSCH (H.); STOUT (N.); FORNER-CORDERO (I.); FLOUR (M.); MOFFATT (C.); SZUBA (A.); MILIC (D.); SZOLNOKY (G.); BRORSON (H.); ABEL (M.); SCHUREN (J.); SCHINGALE (F.); VIGNES (S.); PILLER (N.); DÖLLER (W.) |
| AF : | Dermatology, Medical University of Vienna/Vienna/Autriche (1 aut.); Breast Care Department, National Naval Medical Center/Bethesda, MD/Etats-Unis (2 aut.); Physical Medicine and Rehabilitation/Valencia/Espagne (3 aut.); Dermatology, University Hospital KU Leuven/Belgique (4 aut.); Glasgow Medical School/Glasgow/Royaume-Uni (5 aut.); Department of Internal Medicine, Wroclaw Medical University/Wroclaw/Pologne (6 aut.); Department of Physiotherapy, Wroclaw School of Physical Education/Wroclaw/Pologne (6 aut.); Clinic for Vascular Surgery, University Clinical Centre Nis/Nis/Serbie (7 aut.); Department of Dermatology and Allergology, University of Szeged/Szeged/Hongrie (8 aut.); Department of Clinical Sciences Malmö, Lund University, Plastic and Reconstructive Surgery, Malmö University Hospital/Malmö/Suède (9 aut.); Lohmann & Rauscher/Rengsdorf/Allemagne (10 aut.); Medical Markets Laboratory/Neuss/Allemagne (11 aut.); Lympho-Opt Clinic/Pommelsbrunn/Allemagne (12 aut.); Department of Lymphology, Hôpital Cognacq-Jay/Paris/France (13 aut.); Department of Surgery, School of Medicine, Flinders Medical Centre, Bedford Park South/Australie (14 aut.); Center of Lymphology, General Hospital Wolfsberg/Autriche (15 aut.) |
| DT : | Publication en série; Niveau analytique |
| SO : | International angiology; ISSN 0392-9590; Italie; Da. 2010; Vol. 29; No. 5; Pp. 442-453; Bibl. 81 ref. |
| LA : | Anglais |
| EA : | Aim. A mainstay of lymphedema management involves the use of compression therapy. Compression therapy application is variable at different levels of disease severity. Evidence is scant to direct clinicians in best practice regarding compression therapy use. Further, compression clinical trials are fragmented and poorly extrapolable to the greater population. An ideal construct for conducting clinical trials in regards to compression therapy will promote parallel global initiatives based on a standard research agenda. The purpose of this article is to review current evidence in practice regarding compression therapy for BCRL management and based on this evidence, offer an expert consensus recommendation for a research agenda and prescriptive trials. Recommendations herein focus solely on compression interventions. Methods. This document represents the proceedings of a session organized by the International Compression Club (ICC) in June 2009 in Ponzano (Veneto, Italy). The purpose of the meeting was to enable a group of experts to discuss the existing evidence for compression treatment in breast cancer related lymphedema (BCRL) concentrating on areas where randomized controlled trials (RCTs) are lacking. Results. The current body of research suggests efficacy of compression interventions in the treatment and management of lymphedema. However, studies to date have failed to adequately address various forms of compression therapy and their optimal application in BCRL. We offer recommendations for standardized compression research trials for prophylaxis of arm lymphedema and for the management of chronic BCRL. Suggestions are also made regarding; inclusion and exclusion criteria, measurement methodology and additional variables of interest for researchers to capture. Conclusion. This document should inform future research trials in compression therapy and serve as a guide to clinical researchers, industry researchers and lymphologists regarding the strengths, weaknesses and shortcomings of the current literature. By providing this construct for research trials, the authors aim to support evidence-based therapy interventions, promote a cohesive, standardized and informative body of literature to enhance clinical outcomes, improve the quality of future research trials, inform industry innovation and guide policy related to BCRL. |
| CC : | 002B12B03; 002B02G |
| FD : | Cancer du sein; Lymphoedème; Pathologie de l'appareil circulatoire; Traitement; Bandage; Tumeur sein |
| FG : | Tumeur maligne; Cancer; Pathologie de la glande mammaire; Pathologie du sein; Pathologie des vaisseaux lymphatiques |
| ED : | Breast cancer; Lymphedema; Cardiovascular disease; Treatment; Bandage; Breast tumor |
| EG : | Malignant tumor; Cancer; Mammary gland diseases; Breast disease; Lymphatic vessel disease |
| SD : | Cáncer del pecho; Linfedema; Aparato circulatorio patología; Tratamiento; Vendaje; Tumor pecho |
| LO : | INIST-19982.354000193548450110 |
| ID : | 11-0052630 |
Links to Exploration step
Pascal:11-0052630Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Clinical trials needed to evaluate compression therapy in breast cancer related lymphedema (BCRL). Proposals from an expert group</title><author><name sortKey="Partsch, H" sort="Partsch, H" uniqKey="Partsch H" first="H." last="Partsch">H. Partsch</name><affiliation><inist:fA14 i1="01"><s1>Dermatology, Medical University of Vienna</s1><s2>Vienna</s2><s3>AUT</s3><sZ>1 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Stout, N" sort="Stout, N" uniqKey="Stout N" first="N." last="Stout">N. Stout</name><affiliation><inist:fA14 i1="02"><s1>Breast Care Department, National Naval Medical Center</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Forner Cordero, I" sort="Forner Cordero, I" uniqKey="Forner Cordero I" first="I." last="Forner-Cordero">I. Forner-Cordero</name><affiliation><inist:fA14 i1="03"><s1>Physical Medicine and Rehabilitation</s1><s2>Valencia</s2><s3>ESP</s3><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Flour, M" sort="Flour, M" uniqKey="Flour M" first="M." last="Flour">M. Flour</name><affiliation><inist:fA14 i1="04"><s1>Dermatology, University Hospital KU Leuven</s1><s3>BEL</s3><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Moffatt, C" sort="Moffatt, C" uniqKey="Moffatt C" first="C." last="Moffatt">C. Moffatt</name><affiliation><inist:fA14 i1="05"><s1>Glasgow Medical School</s1><s2>Glasgow</s2><s3>GBR</s3><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Szuba, A" sort="Szuba, A" uniqKey="Szuba A" first="A." last="Szuba">A. Szuba</name><affiliation><inist:fA14 i1="06"><s1>Department of Internal Medicine, Wroclaw Medical University</s1><s2>Wroclaw</s2><s3>POL</s3><sZ>6 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="07"><s1>Department of Physiotherapy, Wroclaw School of Physical Education</s1><s2>Wroclaw</s2><s3>POL</s3><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Milic, D" sort="Milic, D" uniqKey="Milic D" first="D." last="Milic">D. Milic</name><affiliation><inist:fA14 i1="08"><s1>Clinic for Vascular Surgery, University Clinical Centre Nis</s1><s2>Nis</s2><s3>SRB</s3><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Szolnoky, G" sort="Szolnoky, G" uniqKey="Szolnoky G" first="G." last="Szolnoky">G. Szolnoky</name><affiliation><inist:fA14 i1="09"><s1>Department of Dermatology and Allergology, University of Szeged</s1><s2>Szeged</s2><s3>HUN</s3><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Brorson, H" sort="Brorson, H" uniqKey="Brorson H" first="H." last="Brorson">H. Brorson</name><affiliation><inist:fA14 i1="10"><s1>Department of Clinical Sciences Malmö, Lund University, Plastic and Reconstructive Surgery, Malmö University Hospital</s1><s2>Malmö</s2><s3>SWE</s3><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Abel, M" sort="Abel, M" uniqKey="Abel M" first="M." last="Abel">M. Abel</name><affiliation><inist:fA14 i1="11"><s1>Lohmann & Rauscher</s1><s2>Rengsdorf</s2><s3>DEU</s3><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Schuren, J" sort="Schuren, J" uniqKey="Schuren J" first="J." last="Schuren">J. Schuren</name><affiliation><inist:fA14 i1="12"><s1>Medical Markets Laboratory</s1><s2>Neuss</s2><s3>DEU</s3><sZ>11 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Schingale, F" sort="Schingale, F" uniqKey="Schingale F" first="F." last="Schingale">F. Schingale</name><affiliation><inist:fA14 i1="13"><s1>Lympho-Opt Clinic</s1><s2>Pommelsbrunn</s2><s3>DEU</s3><sZ>12 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Vignes, S" sort="Vignes, S" uniqKey="Vignes S" first="S." last="Vignes">S. Vignes</name><affiliation><inist:fA14 i1="14"><s1>Department of Lymphology, Hôpital Cognacq-Jay</s1><s2>Paris</s2><s3>FRA</s3><sZ>13 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Piller, N" sort="Piller, N" uniqKey="Piller N" first="N." last="Piller">N. Piller</name><affiliation><inist:fA14 i1="15"><s1>Department of Surgery, School of Medicine, Flinders Medical Centre, Bedford Park South</s1><s3>AUS</s3><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Doller, W" sort="Doller, W" uniqKey="Doller W" first="W." last="Döller">W. Döller</name><affiliation><inist:fA14 i1="16"><s1>Center of Lymphology, General Hospital Wolfsberg</s1><s3>AUT</s3><sZ>15 aut.</sZ></inist:fA14></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">11-0052630</idno><date when="2010">2010</date><idno type="stanalyst">PASCAL 11-0052630 INIST</idno><idno type="RBID">Pascal:11-0052630</idno><idno type="wicri:Area/PascalFrancis/Corpus">000213</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Clinical trials needed to evaluate compression therapy in breast cancer related lymphedema (BCRL). Proposals from an expert group</title><author><name sortKey="Partsch, H" sort="Partsch, H" uniqKey="Partsch H" first="H." last="Partsch">H. Partsch</name><affiliation><inist:fA14 i1="01"><s1>Dermatology, Medical University of Vienna</s1><s2>Vienna</s2><s3>AUT</s3><sZ>1 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Stout, N" sort="Stout, N" uniqKey="Stout N" first="N." last="Stout">N. Stout</name><affiliation><inist:fA14 i1="02"><s1>Breast Care Department, National Naval Medical Center</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Forner Cordero, I" sort="Forner Cordero, I" uniqKey="Forner Cordero I" first="I." last="Forner-Cordero">I. Forner-Cordero</name><affiliation><inist:fA14 i1="03"><s1>Physical Medicine and Rehabilitation</s1><s2>Valencia</s2><s3>ESP</s3><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Flour, M" sort="Flour, M" uniqKey="Flour M" first="M." last="Flour">M. Flour</name><affiliation><inist:fA14 i1="04"><s1>Dermatology, University Hospital KU Leuven</s1><s3>BEL</s3><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Moffatt, C" sort="Moffatt, C" uniqKey="Moffatt C" first="C." last="Moffatt">C. Moffatt</name><affiliation><inist:fA14 i1="05"><s1>Glasgow Medical School</s1><s2>Glasgow</s2><s3>GBR</s3><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Szuba, A" sort="Szuba, A" uniqKey="Szuba A" first="A." last="Szuba">A. Szuba</name><affiliation><inist:fA14 i1="06"><s1>Department of Internal Medicine, Wroclaw Medical University</s1><s2>Wroclaw</s2><s3>POL</s3><sZ>6 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="07"><s1>Department of Physiotherapy, Wroclaw School of Physical Education</s1><s2>Wroclaw</s2><s3>POL</s3><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Milic, D" sort="Milic, D" uniqKey="Milic D" first="D." last="Milic">D. Milic</name><affiliation><inist:fA14 i1="08"><s1>Clinic for Vascular Surgery, University Clinical Centre Nis</s1><s2>Nis</s2><s3>SRB</s3><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Szolnoky, G" sort="Szolnoky, G" uniqKey="Szolnoky G" first="G." last="Szolnoky">G. Szolnoky</name><affiliation><inist:fA14 i1="09"><s1>Department of Dermatology and Allergology, University of Szeged</s1><s2>Szeged</s2><s3>HUN</s3><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Brorson, H" sort="Brorson, H" uniqKey="Brorson H" first="H." last="Brorson">H. Brorson</name><affiliation><inist:fA14 i1="10"><s1>Department of Clinical Sciences Malmö, Lund University, Plastic and Reconstructive Surgery, Malmö University Hospital</s1><s2>Malmö</s2><s3>SWE</s3><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Abel, M" sort="Abel, M" uniqKey="Abel M" first="M." last="Abel">M. Abel</name><affiliation><inist:fA14 i1="11"><s1>Lohmann & Rauscher</s1><s2>Rengsdorf</s2><s3>DEU</s3><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Schuren, J" sort="Schuren, J" uniqKey="Schuren J" first="J." last="Schuren">J. Schuren</name><affiliation><inist:fA14 i1="12"><s1>Medical Markets Laboratory</s1><s2>Neuss</s2><s3>DEU</s3><sZ>11 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Schingale, F" sort="Schingale, F" uniqKey="Schingale F" first="F." last="Schingale">F. Schingale</name><affiliation><inist:fA14 i1="13"><s1>Lympho-Opt Clinic</s1><s2>Pommelsbrunn</s2><s3>DEU</s3><sZ>12 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Vignes, S" sort="Vignes, S" uniqKey="Vignes S" first="S." last="Vignes">S. Vignes</name><affiliation><inist:fA14 i1="14"><s1>Department of Lymphology, Hôpital Cognacq-Jay</s1><s2>Paris</s2><s3>FRA</s3><sZ>13 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Piller, N" sort="Piller, N" uniqKey="Piller N" first="N." last="Piller">N. Piller</name><affiliation><inist:fA14 i1="15"><s1>Department of Surgery, School of Medicine, Flinders Medical Centre, Bedford Park South</s1><s3>AUS</s3><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Doller, W" sort="Doller, W" uniqKey="Doller W" first="W." last="Döller">W. Döller</name><affiliation><inist:fA14 i1="16"><s1>Center of Lymphology, General Hospital Wolfsberg</s1><s3>AUT</s3><sZ>15 aut.</sZ></inist:fA14></affiliation></author></analytic><series><title level="j" type="main">International angiology</title><title level="j" type="abbreviated">Int. angiol.</title><idno type="ISSN">0392-9590</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">International angiology</title><title level="j" type="abbreviated">Int. angiol.</title><idno type="ISSN">0392-9590</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bandage</term><term>Breast cancer</term><term>Breast tumor</term><term>Cardiovascular disease</term><term>Lymphedema</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Cancer du sein</term><term>Lymphoedème</term><term>Pathologie de l'appareil circulatoire</term><term>Traitement</term><term>Bandage</term><term>Tumeur sein</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Aim. A mainstay of lymphedema management involves the use of compression therapy. Compression therapy application is variable at different levels of disease severity. Evidence is scant to direct clinicians in best practice regarding compression therapy use. Further, compression clinical trials are fragmented and poorly extrapolable to the greater population. An ideal construct for conducting clinical trials in regards to compression therapy will promote parallel global initiatives based on a standard research agenda. The purpose of this article is to review current evidence in practice regarding compression therapy for BCRL management and based on this evidence, offer an expert consensus recommendation for a research agenda and prescriptive trials. Recommendations herein focus solely on compression interventions. Methods. This document represents the proceedings of a session organized by the International Compression Club (ICC) in June 2009 in Ponzano (Veneto, Italy). The purpose of the meeting was to enable a group of experts to discuss the existing evidence for compression treatment in breast cancer related lymphedema (BCRL) concentrating on areas where randomized controlled trials (RCTs) are lacking. Results. The current body of research suggests efficacy of compression interventions in the treatment and management of lymphedema. However, studies to date have failed to adequately address various forms of compression therapy and their optimal application in BCRL. We offer recommendations for standardized compression research trials for prophylaxis of arm lymphedema and for the management of chronic BCRL. Suggestions are also made regarding; inclusion and exclusion criteria, measurement methodology and additional variables of interest for researchers to capture. Conclusion. This document should inform future research trials in compression therapy and serve as a guide to clinical researchers, industry researchers and lymphologists regarding the strengths, weaknesses and shortcomings of the current literature. By providing this construct for research trials, the authors aim to support evidence-based therapy interventions, promote a cohesive, standardized and informative body of literature to enhance clinical outcomes, improve the quality of future research trials, inform industry innovation and guide policy related to BCRL.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0392-9590</s0></fA01><fA03 i2="1"><s0>Int. angiol.</s0></fA03><fA05><s2>29</s2></fA05><fA06><s2>5</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Clinical trials needed to evaluate compression therapy in breast cancer related lymphedema (BCRL). Proposals from an expert group</s1></fA08><fA11 i1="01" i2="1"><s1>PARTSCH (H.)</s1></fA11><fA11 i1="02" i2="1"><s1>STOUT (N.)</s1></fA11><fA11 i1="03" i2="1"><s1>FORNER-CORDERO (I.)</s1></fA11><fA11 i1="04" i2="1"><s1>FLOUR (M.)</s1></fA11><fA11 i1="05" i2="1"><s1>MOFFATT (C.)</s1></fA11><fA11 i1="06" i2="1"><s1>SZUBA (A.)</s1></fA11><fA11 i1="07" i2="1"><s1>MILIC (D.)</s1></fA11><fA11 i1="08" i2="1"><s1>SZOLNOKY (G.)</s1></fA11><fA11 i1="09" i2="1"><s1>BRORSON (H.)</s1></fA11><fA11 i1="10" i2="1"><s1>ABEL (M.)</s1></fA11><fA11 i1="11" i2="1"><s1>SCHUREN (J.)</s1></fA11><fA11 i1="12" i2="1"><s1>SCHINGALE (F.)</s1></fA11><fA11 i1="13" i2="1"><s1>VIGNES (S.)</s1></fA11><fA11 i1="14" i2="1"><s1>PILLER (N.)</s1></fA11><fA11 i1="15" i2="1"><s1>DÖLLER (W.)</s1></fA11><fA14 i1="01"><s1>Dermatology, Medical University of Vienna</s1><s2>Vienna</s2><s3>AUT</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Breast Care Department, National Naval Medical Center</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>2 aut.</sZ></fA14><fA14 i1="03"><s1>Physical Medicine and Rehabilitation</s1><s2>Valencia</s2><s3>ESP</s3><sZ>3 aut.</sZ></fA14><fA14 i1="04"><s1>Dermatology, University Hospital KU Leuven</s1><s3>BEL</s3><sZ>4 aut.</sZ></fA14><fA14 i1="05"><s1>Glasgow Medical School</s1><s2>Glasgow</s2><s3>GBR</s3><sZ>5 aut.</sZ></fA14><fA14 i1="06"><s1>Department of Internal Medicine, Wroclaw Medical University</s1><s2>Wroclaw</s2><s3>POL</s3><sZ>6 aut.</sZ></fA14><fA14 i1="07"><s1>Department of Physiotherapy, Wroclaw School of Physical Education</s1><s2>Wroclaw</s2><s3>POL</s3><sZ>6 aut.</sZ></fA14><fA14 i1="08"><s1>Clinic for Vascular Surgery, University Clinical Centre Nis</s1><s2>Nis</s2><s3>SRB</s3><sZ>7 aut.</sZ></fA14><fA14 i1="09"><s1>Department of Dermatology and Allergology, University of Szeged</s1><s2>Szeged</s2><s3>HUN</s3><sZ>8 aut.</sZ></fA14><fA14 i1="10"><s1>Department of Clinical Sciences Malmö, Lund University, Plastic and Reconstructive Surgery, Malmö University Hospital</s1><s2>Malmö</s2><s3>SWE</s3><sZ>9 aut.</sZ></fA14><fA14 i1="11"><s1>Lohmann & Rauscher</s1><s2>Rengsdorf</s2><s3>DEU</s3><sZ>10 aut.</sZ></fA14><fA14 i1="12"><s1>Medical Markets Laboratory</s1><s2>Neuss</s2><s3>DEU</s3><sZ>11 aut.</sZ></fA14><fA14 i1="13"><s1>Lympho-Opt Clinic</s1><s2>Pommelsbrunn</s2><s3>DEU</s3><sZ>12 aut.</sZ></fA14><fA14 i1="14"><s1>Department of Lymphology, Hôpital Cognacq-Jay</s1><s2>Paris</s2><s3>FRA</s3><sZ>13 aut.</sZ></fA14><fA14 i1="15"><s1>Department of Surgery, School of Medicine, Flinders Medical Centre, Bedford Park South</s1><s3>AUS</s3><sZ>14 aut.</sZ></fA14><fA14 i1="16"><s1>Center of Lymphology, General Hospital Wolfsberg</s1><s3>AUT</s3><sZ>15 aut.</sZ></fA14><fA20><s1>442-453</s1></fA20><fA21><s1>2010</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>19982</s2><s5>354000193548450110</s5></fA43><fA44><s0>0000</s0><s1>© 2011 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>81 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>11-0052630</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>International angiology</s0></fA64><fA66 i1="01"><s0>ITA</s0></fA66><fC01 i1="01" l="ENG"><s0>Aim. A mainstay of lymphedema management involves the use of compression therapy. Compression therapy application is variable at different levels of disease severity. Evidence is scant to direct clinicians in best practice regarding compression therapy use. Further, compression clinical trials are fragmented and poorly extrapolable to the greater population. An ideal construct for conducting clinical trials in regards to compression therapy will promote parallel global initiatives based on a standard research agenda. The purpose of this article is to review current evidence in practice regarding compression therapy for BCRL management and based on this evidence, offer an expert consensus recommendation for a research agenda and prescriptive trials. Recommendations herein focus solely on compression interventions. Methods. This document represents the proceedings of a session organized by the International Compression Club (ICC) in June 2009 in Ponzano (Veneto, Italy). The purpose of the meeting was to enable a group of experts to discuss the existing evidence for compression treatment in breast cancer related lymphedema (BCRL) concentrating on areas where randomized controlled trials (RCTs) are lacking. Results. The current body of research suggests efficacy of compression interventions in the treatment and management of lymphedema. However, studies to date have failed to adequately address various forms of compression therapy and their optimal application in BCRL. We offer recommendations for standardized compression research trials for prophylaxis of arm lymphedema and for the management of chronic BCRL. Suggestions are also made regarding; inclusion and exclusion criteria, measurement methodology and additional variables of interest for researchers to capture. Conclusion. This document should inform future research trials in compression therapy and serve as a guide to clinical researchers, industry researchers and lymphologists regarding the strengths, weaknesses and shortcomings of the current literature. By providing this construct for research trials, the authors aim to support evidence-based therapy interventions, promote a cohesive, standardized and informative body of literature to enhance clinical outcomes, improve the quality of future research trials, inform industry innovation and guide policy related to BCRL.</s0></fC01><fC02 i1="01" i2="X"><s0>002B12B03</s0></fC02><fC02 i1="02" i2="X"><s0>002B02G</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Cancer du sein</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Breast cancer</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Cáncer del pecho</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Lymphoedème</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Lymphedema</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Linfedema</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Pathologie de l'appareil circulatoire</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Cardiovascular disease</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Traitement</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Treatment</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Tratamiento</s0><s5>09</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Bandage</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Bandage</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Vendaje</s0><s5>10</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Tumeur sein</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Breast tumor</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Tumor pecho</s0><s4>CD</s4><s5>96</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Tumeur maligne</s0><s2>NM</s2><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Malignant tumor</s0><s2>NM</s2><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Tumor maligno</s0><s2>NM</s2><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Cáncer</s0><s2>NM</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Pathologie de la glande mammaire</s0><s2>NM</s2><s5>38</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Mammary gland diseases</s0><s2>NM</s2><s5>38</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Glándula mamaria patología</s0><s2>NM</s2><s5>38</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du sein</s0><s2>NM</s2><s5>39</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Breast disease</s0><s2>NM</s2><s5>39</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Seno patología</s0><s2>NM</s2><s5>39</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Pathologie des vaisseaux lymphatiques</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Lymphatic vessel disease</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Linfático patología</s0><s5>40</s5></fC07><fN21><s1>031</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard><server><NO>PASCAL 11-0052630 INIST</NO><ET>Clinical trials needed to evaluate compression therapy in breast cancer related lymphedema (BCRL). Proposals from an expert group</ET><AU>PARTSCH (H.); STOUT (N.); FORNER-CORDERO (I.); FLOUR (M.); MOFFATT (C.); SZUBA (A.); MILIC (D.); SZOLNOKY (G.); BRORSON (H.); ABEL (M.); SCHUREN (J.); SCHINGALE (F.); VIGNES (S.); PILLER (N.); DÖLLER (W.)</AU><AF>Dermatology, Medical University of Vienna/Vienna/Autriche (1 aut.); Breast Care Department, National Naval Medical Center/Bethesda, MD/Etats-Unis (2 aut.); Physical Medicine and Rehabilitation/Valencia/Espagne (3 aut.); Dermatology, University Hospital KU Leuven/Belgique (4 aut.); Glasgow Medical School/Glasgow/Royaume-Uni (5 aut.); Department of Internal Medicine, Wroclaw Medical University/Wroclaw/Pologne (6 aut.); Department of Physiotherapy, Wroclaw School of Physical Education/Wroclaw/Pologne (6 aut.); Clinic for Vascular Surgery, University Clinical Centre Nis/Nis/Serbie (7 aut.); Department of Dermatology and Allergology, University of Szeged/Szeged/Hongrie (8 aut.); Department of Clinical Sciences Malmö, Lund University, Plastic and Reconstructive Surgery, Malmö University Hospital/Malmö/Suède (9 aut.); Lohmann & Rauscher/Rengsdorf/Allemagne (10 aut.); Medical Markets Laboratory/Neuss/Allemagne (11 aut.); Lympho-Opt Clinic/Pommelsbrunn/Allemagne (12 aut.); Department of Lymphology, Hôpital Cognacq-Jay/Paris/France (13 aut.); Department of Surgery, School of Medicine, Flinders Medical Centre, Bedford Park South/Australie (14 aut.); Center of Lymphology, General Hospital Wolfsberg/Autriche (15 aut.)</AF><DT>Publication en série; Niveau analytique</DT><SO>International angiology; ISSN 0392-9590; Italie; Da. 2010; Vol. 29; No. 5; Pp. 442-453; Bibl. 81 ref.</SO><LA>Anglais</LA><EA>Aim. A mainstay of lymphedema management involves the use of compression therapy. Compression therapy application is variable at different levels of disease severity. Evidence is scant to direct clinicians in best practice regarding compression therapy use. Further, compression clinical trials are fragmented and poorly extrapolable to the greater population. An ideal construct for conducting clinical trials in regards to compression therapy will promote parallel global initiatives based on a standard research agenda. The purpose of this article is to review current evidence in practice regarding compression therapy for BCRL management and based on this evidence, offer an expert consensus recommendation for a research agenda and prescriptive trials. Recommendations herein focus solely on compression interventions. Methods. This document represents the proceedings of a session organized by the International Compression Club (ICC) in June 2009 in Ponzano (Veneto, Italy). The purpose of the meeting was to enable a group of experts to discuss the existing evidence for compression treatment in breast cancer related lymphedema (BCRL) concentrating on areas where randomized controlled trials (RCTs) are lacking. Results. The current body of research suggests efficacy of compression interventions in the treatment and management of lymphedema. However, studies to date have failed to adequately address various forms of compression therapy and their optimal application in BCRL. We offer recommendations for standardized compression research trials for prophylaxis of arm lymphedema and for the management of chronic BCRL. Suggestions are also made regarding; inclusion and exclusion criteria, measurement methodology and additional variables of interest for researchers to capture. Conclusion. This document should inform future research trials in compression therapy and serve as a guide to clinical researchers, industry researchers and lymphologists regarding the strengths, weaknesses and shortcomings of the current literature. By providing this construct for research trials, the authors aim to support evidence-based therapy interventions, promote a cohesive, standardized and informative body of literature to enhance clinical outcomes, improve the quality of future research trials, inform industry innovation and guide policy related to BCRL.</EA><CC>002B12B03; 002B02G</CC><FD>Cancer du sein; Lymphoedème; Pathologie de l'appareil circulatoire; Traitement; Bandage; Tumeur sein</FD><FG>Tumeur maligne; Cancer; Pathologie de la glande mammaire; Pathologie du sein; Pathologie des vaisseaux lymphatiques</FG><ED>Breast cancer; Lymphedema; Cardiovascular disease; Treatment; Bandage; Breast tumor</ED><EG>Malignant tumor; Cancer; Mammary gland diseases; Breast disease; Lymphatic vessel disease</EG><SD>Cáncer del pecho; Linfedema; Aparato circulatorio patología; Tratamiento; Vendaje; Tumor pecho</SD><LO>INIST-19982.354000193548450110</LO><ID>11-0052630</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000213 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000213 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:11-0052630
|texte= Clinical trials needed to evaluate compression therapy in breast cancer related lymphedema (BCRL). Proposals from an expert group
}}
| This area was generated with Dilib version V0.6.31. |  |